Weiyel Launches Hepatitis C Virus RNA Standard Material Series

In the field of hepatitis C diagnosis and treatment, accurate viral typing and quantitative detection are core prerequisites for developing individualized treatment plans and evaluating treatment effectiveness, directly impacting patient treatment quality and prognosis. Recently, Weiyel officially launched its Hepatitis C Virus RNA Detection Standard Material Series. The advent of this series provides a reliable "gold standard" for hepatitis C molecular diagnosis and is expected to further promote the standardization and normalization of hepatitis C diagnosis and treatment in my country.

As a key support for hepatitis C diagnosis and treatment, the accuracy and coverage of standard materials directly affect the reliability of test results. Weiyel's newly launched Hepatitis C Virus RNA Standard Material Series is precisely developed for common clinical hepatitis C virus subtypes, forming two core product matrices:

Hepatitis C Virus Type 1 RNA Standard Material: Covers the most prevalent subtypes globally, providing a core standard for basic diagnosis and treatment.

Hepatitis C Virus Type 2 RNA Standard Material: Targets another important subtype, ensuring the accuracy of typing detection.

In addition to its advantages in accurate typing, this series of reference materials also has broad clinical application value. This series of reference materials is suitable for the calibration, interlaboratory quality assessment, and dynamic monitoring of viral load in HCV nucleic acid quantitative detection kits, helping to improve the standardization and normalization of hepatitis C diagnosis and treatment in my country.

Product details are as follows:

In the future, Weiyel will continue to focus on the metrological needs of the medical and health field, continuously developing more high-quality reference materials and testing solutions, contributing to improving the level of medical testing in my country and promoting the standardized diagnosis and treatment of diseases such as hepatitis C.